388 related articles for article (PubMed ID: 19016756)
41. Population-based screening for breast and ovarian cancer risk due to BRCA1 and BRCA2.
Gabai-Kapara E; Lahad A; Kaufman B; Friedman E; Segev S; Renbaum P; Beeri R; Gal M; Grinshpun-Cohen J; Djemal K; Mandell JB; Lee MK; Beller U; Catane R; King MC; Levy-Lahad E
Proc Natl Acad Sci U S A; 2014 Sep; 111(39):14205-10. PubMed ID: 25192939
[TBL] [Abstract][Full Text] [Related]
42. Evaluation of BRCA1 and BRCA2 mutations and risk-prediction models in a typical Asian country (Malaysia) with a relatively low incidence of breast cancer.
Thirthagiri E; Lee SY; Kang P; Lee DS; Toh GT; Selamat S; Yoon SY; Taib NA; Thong MK; Yip CH; Teo SH
Breast Cancer Res; 2008; 10(4):R59. PubMed ID: 18627636
[TBL] [Abstract][Full Text] [Related]
43. Prevalence of BRCA1 and BRCA2 mutations in non-familial breast cancer patients with high risks in Korea: the Korean Hereditary Breast Cancer (KOHBRA) Study.
Son BH; Ahn SH; Kim SW; Kang E; Park SK; Lee MH; Noh WC; Kim LS; Jung Y; Kim KS; Noh DY; Moon BI; Suh YJ; Lee JE; Choi DH; Kim SY; Jung SH; Yom CK; Lee H; Yang JH;
Breast Cancer Res Treat; 2012 Jun; 133(3):1143-52. PubMed ID: 22382806
[TBL] [Abstract][Full Text] [Related]
44. BRCA1 and BRCA2 mutations in women with familial or early-onset breast/ovarian cancer in the Czech Republic.
Foretova L; Machackova E; Navratilova M; Pavlu H; Hruba M; Lukesova M; Valik D
Hum Mutat; 2004 Apr; 23(4):397-8. PubMed ID: 15024741
[TBL] [Abstract][Full Text] [Related]
45. Prevalence of BRCA1 and BRCA2 genomic rearrangements in a cohort of consecutive Italian breast and/or ovarian cancer families.
Buffone A; Capalbo C; Ricevuto E; Sidoni T; Ottini L; Falchetti M; Cortesi E; Marchetti P; Scambia G; Tomao S; Rinaldi C; Zani M; Ferraro S; Frati L; Screpanti I; Gulino A; Giannini G
Breast Cancer Res Treat; 2007 Dec; 106(2):289-96. PubMed ID: 17333342
[TBL] [Abstract][Full Text] [Related]
46. The presence of hereditary BRCA1 gene mutations in women with familial breast or ovarian cancer and the frequency of occurrence of these tumours in their relatives.
Skasko E; Paszko Z; Niwińska A; Kwiatkowska E; Kruczek A; Pieńkowski T
Eur J Gynaecol Oncol; 2004; 25(4):470-4. PubMed ID: 15285306
[TBL] [Abstract][Full Text] [Related]
47. Double heterozygosity in the BRCA1 and BRCA2 genes in the Jewish population.
Lavie O; Narod S; Lejbkowicz F; Dishon S; Goldberg Y; Gemer O; Rennert G
Ann Oncol; 2011 Apr; 22(4):964-966. PubMed ID: 20924075
[TBL] [Abstract][Full Text] [Related]
48. BRCA1 and BRCA2 mutations account for a large proportion of ovarian carcinoma cases.
Pal T; Permuth-Wey J; Betts JA; Krischer JP; Fiorica J; Arango H; LaPolla J; Hoffman M; Martino MA; Wakeley K; Wilbanks G; Nicosia S; Cantor A; Sutphen R
Cancer; 2005 Dec; 104(12):2807-16. PubMed ID: 16284991
[TBL] [Abstract][Full Text] [Related]
49. Germline BRCA1 mutation analysis in Indian breast/ovarian cancer families.
Kumar BV; Lakhotia S; Ankathil R; Madhavan J; Jayaprakash PG; Nair MK; Somasundaram K
Cancer Biol Ther; 2002; 1(1):18-21. PubMed ID: 12170759
[TBL] [Abstract][Full Text] [Related]
50. [The prevalence of BRCA1 mutations among families at high-risk of breast and ovarian cancer in province of Malopolska between 2004-2009].
Blecharz P; Szatkowski W; Klimek M; Urbański K
Przegl Lek; 2009; 66(12):1046-8. PubMed ID: 20514903
[TBL] [Abstract][Full Text] [Related]
51. BRCA1 and BRCA2 mutation status and cancer family history of Danish women affected with multifocal or bilateral breast cancer at a young age.
Bergthorsson JT; Ejlertsen B; Olsen JH; Borg A; Nielsen KV; Barkardottir RB; Klausen S; Mouridsen HT; Winther K; Fenger K; Niebuhr A; Harboe TL; Niebuhr E
J Med Genet; 2001 Jun; 38(6):361-8. PubMed ID: 11389159
[TBL] [Abstract][Full Text] [Related]
52. Screening for BRCA1, BRCA2, CHEK2, PALB2, BRIP1, RAD50, and CDH1 mutations in high-risk Finnish BRCA1/2-founder mutation-negative breast and/or ovarian cancer individuals.
Kuusisto KM; Bebel A; Vihinen M; Schleutker J; Sallinen SL
Breast Cancer Res; 2011 Feb; 13(1):R20. PubMed ID: 21356067
[TBL] [Abstract][Full Text] [Related]
53. BRCA1 and BRCA2 germline mutation spectrum in hereditary breast/ovarian cancer families from Maghrebian countries.
Cherbal F; Bakour R; Adane S; Boualga K
Breast Dis; 2012; 34(1):1-8. PubMed ID: 23697973
[TBL] [Abstract][Full Text] [Related]
54. Prevalence of BRCA1 and BRCA2 mutations in Pakistani breast and ovarian cancer patients.
Rashid MU; Zaidi A; Torres D; Sultan F; Benner A; Naqvi B; Shakoori AR; Seidel-Renkert A; Farooq H; Narod S; Amin A; Hamann U
Int J Cancer; 2006 Dec; 119(12):2832-9. PubMed ID: 16998791
[TBL] [Abstract][Full Text] [Related]
55. Prevalence and type of BRCA mutations in Hispanics undergoing genetic cancer risk assessment in the southwestern United States: a report from the Clinical Cancer Genetics Community Research Network.
Weitzel JN; Clague J; Martir-Negron A; Ogaz R; Herzog J; Ricker C; Jungbluth C; Cina C; Duncan P; Unzeitig G; Saldivar JS; Beattie M; Feldman N; Sand S; Port D; Barragan DI; John EM; Neuhausen SL; Larson GP
J Clin Oncol; 2013 Jan; 31(2):210-6. PubMed ID: 23233716
[TBL] [Abstract][Full Text] [Related]
56. Clinical characteristics of individuals with germline mutations in BRCA1 and BRCA2: analysis of 10,000 individuals.
Frank TS; Deffenbaugh AM; Reid JE; Hulick M; Ward BE; Lingenfelter B; Gumpper KL; Scholl T; Tavtigian SV; Pruss DR; Critchfield GC
J Clin Oncol; 2002 Mar; 20(6):1480-90. PubMed ID: 11896095
[TBL] [Abstract][Full Text] [Related]
57. A role of BRCA1 and BRCA2 germline mutations in breast cancer susceptibility within Sardinian population.
Palomba G; Loi A; Uras A; Fancello P; Piras G; Gabbas A; Cossu A; Budroni M; Contu A; Tanda F; Farris A; Orrù S; Floris C; Pisano M; Lovicu M; Santona MC; Landriscina G; Crisponi L; Palmieri G; Monne M
BMC Cancer; 2009 Jul; 9():245. PubMed ID: 19619314
[TBL] [Abstract][Full Text] [Related]
58. Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers.
Kuchenbaecker KB; Hopper JL; Barnes DR; Phillips KA; Mooij TM; Roos-Blom MJ; Jervis S; van Leeuwen FE; Milne RL; Andrieu N; Goldgar DE; Terry MB; Rookus MA; Easton DF; Antoniou AC; ; McGuffog L; Evans DG; Barrowdale D; Frost D; Adlard J; Ong KR; Izatt L; Tischkowitz M; Eeles R; Davidson R; Hodgson S; Ellis S; Nogues C; Lasset C; Stoppa-Lyonnet D; Fricker JP; Faivre L; Berthet P; Hooning MJ; van der Kolk LE; Kets CM; Adank MA; John EM; Chung WK; Andrulis IL; Southey M; Daly MB; Buys SS; Osorio A; Engel C; Kast K; Schmutzler RK; Caldes T; Jakubowska A; Simard J; Friedlander ML; McLachlan SA; Machackova E; Foretova L; Tan YY; Singer CF; Olah E; Gerdes AM; Arver B; Olsson H
JAMA; 2017 Jun; 317(23):2402-2416. PubMed ID: 28632866
[TBL] [Abstract][Full Text] [Related]
59. Prevalence of BRCA1 and BRCA2 germline mutations in young breast cancer patients: a population-based study.
de Sanjosé S; Léoné M; Bérez V; Izquierdo A; Font R; Brunet JM; Louat T; Vilardell L; Borras J; Viladiu P; Bosch FX; Lenoir GM; Sinilnikova OM
Int J Cancer; 2003 Sep; 106(4):588-593. PubMed ID: 12845657
[TBL] [Abstract][Full Text] [Related]
60. BRCA1 and BRCA2 germline mutational spectrum and evidence for genetic anticipation in Portuguese breast/ovarian cancer families.
Peixoto A; Salgueiro N; Santos C; Varzim G; Rocha P; Soares MJ; Pereira D; Rodrigues H; Bento MJ; Fráguas A; Moura G; Regateiro F; Castedo S; Teixeira MR
Fam Cancer; 2006; 5(4):379-87. PubMed ID: 16826315
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
